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Abstract
When we launched the Journal of Translational Medicine a few months ago, we were interested
primarily in exploring scientific consideration of this discipline. However, as editors of JTM, we have
been contacted almost daily to discuss the problems faced by scientists and clinicians around the
world who are challenging the traditional boundaries of science and medicine. Through these
conversations, we have learned that translational medicine is in fact "lost in translation," inspiring
much angst, many promises and some Federal appropriations. However, little has been done to
substantively promote this important field. Authoritative reviews on the subject are available to the
interested reader [1-7]. In this article, we will address JTM's "constituency" to report what we've
learned about the obstacles to translational medicine from the myriad of phone conversations and
e-mail interactions.
In addressing issues for Translational Medicine, we cate-
gorize the hurdles faced by our colleagues as follows:
Semantics
What's in a name? A name defines a concept which in turn
may shape a vision. Therefore, it may behoove us to estab-
lish a common understanding of the definition of "trans-
lational medicine" to frame our expectations or
frustrations. For most, "translational medicine" (or
"translational research") describes a uni-directional effort
to test in humans novel therapeutic strategies developed
through experimentation. This would suffice if animal or
other experimental models were representative of human
pathology, but this remains to be determined [8-10]. as
well summarized by Herbert Slade's: "there are no good
animal models, but some are useful." In addition, transla-
tional medicine may include the development of new
devices or novel diagnostic tools. Moreover, we suggested
in a previous editorial that "translational medicine" is a
two-way street where the drive to cure should be comple-
mented by the pursuit to understand human diseases and
their complexities [11]. Thus, one important aspect of
translational medicine is going back from the bedside to
the laboratory with observations made in human studies.
This practice might be more constructive, focusing scien-
tific thinking and providing more practical information.
Mario Sznol, a member of JTM Editorial Board, suggested
that Translational Medicine should be defined as a disci-
pline that encompasses:
1. Basic science studies which define the biological effects
of therapeutics in humans
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2. Investigations in humans which define the biology of
disease and provide the scientific foundation for develop-
ment of new or improved therapies for human disease
3. Non-human or non-clinical studies conducted with the
intent to advance therapies to the clinic or to develop
principles for application of therapeutics to human dis-
ease
4. Any clinical trial of a therapythat was initiated based on
#1–3 with any endpoint including toxicity and/or effi-
cacy.
In addition, in the regulatory arena:
5. Translational research may be defined as appropriate
product development for clinical use in various stages of
investigational clinical trial. For example, identity, purity
and potency of a drug product must be studied during the
early stages of the clinical trial. However, these tests must
be in place before implementing phase 3 trials as required
by the regulations.
Establishing a definition of "translational medicine" has
both regulatory and commercial implications. Currently,
a large sector of the biopharmaceutical industry is devoted
to the development of new therapeutic modalities. How-
ever, industry is also concerned with the monitoring of
ever-evolving therapeutic strategies by enhancing the
quality, efficiency and throughput of available methods.
In addition, revolutionary progress in genomics, func-
tional genomics and proteomics may result in the identi-
fication of new diagnostic and/or prognostic parameters
and define therapeutic end-points based on novel surro-
gate markers relevant to disease progression and response
to therapy [5,12-16]. Are public, government, academic
and industry interests united in supporting this important
direction of translational medicine?
Advocacy
Translational medicine covers a broad range of scientific,
regulatory and clinical disciplines and there is no single
organization currently in existence to embrace the field in
its globality. Therefore, while scientific and clinical
aspects related to individual fields can be addressed
within the realm of specialized societies, other practical
aspects often related to education, regulation, business
and economic issues remain orphaned, with no focused
outlet through which to address emerging issues. An
organization embracing the complexities of translational
medicine should be considered with the goal of contribut-
ing information to all arenas of the need for translational
efforts.
A translational medicine organization is particularly
important in today's era of federal budget constraints. For
example, most "standard" therapies for cancer do not
affect survival [17], and billions of dollars are spent on
drugs and therapeutic interventions that do not impact
the natural history of most common diseases. Should
advocacy efforts seek to shift funds from other research
areas to translational research? Would it be savvier to join
with other advocates of medical research to increase pub-
lic and congressional awareness of the integrated need to
understand basic as well as human biology? And who
should be responsible for such advocacy? The National
Institutes of Health has recently staked a claim on this
issue by defining a roadmap to accelerate medical discov-
eries to improve human health http://nihroad
map.nih.gov. Should more institutions join the effort?
And how should industry integrate with this effort? To be
effective, barriers will only be removed by the collabora-
tive efforts of multiple system stakeholders [7].
Intellectual
We confess to being baffled by some comments from
reviewers solicited by the Editorial Board of JTM regarding
some of the manuscripts submitted. Reviewers often dis-
miss some JTM submissions as not "hypothesis-driven",
not "mechanistic", but "just" descriptive or discovery-
driven. Such reviewers have often embraced solid hypoth-
eses of their own to which they are strongly attached, like
Manzoni's Donna Prassede who "in the matter of ideas
followed the policy we are told we should follow with
friends – She had only a few, but she was strongly attached
to them" [18]. By their own admission, no objective evi-
dence conclusively supports their hypotheses in the con-
text of human disease, yet loyal they remain.
Unfortunately, hypothesis-driven research alone cannot
meet the needs of translational medicine. This is because
hypotheses derived from complex experimental models
often simply do not translate to human pathology. Thus,
we suggested that discovery-driven research should be
promoted in the context of translational medicine and
should be better referred to as "reality-driven" research
underlining the concept that direct human observation
may direct to the study of hypotheses relevant to human
reality.
Reality-driven research in humans faces obstacles of its
own. First, communication between basic and clinical sci-
entists is rare and sporadic [2]. Few meetings are devoted
primarily to bringing the two entities together to promote
mutually beneficial exchange. The paradigm between
basic and clinical science has oftentimes put these two dis-
ciplines at odds with each other. It is not in the interest of
basic scientists to accept changes unless publishing and
study section standards are realigned to reward clinical
relevance. Clinical scientists for their part are often over-Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/14
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whelmed with information coming from the basic science
community. How can such a wealth of information be
processed into a useful compendium that might contrib-
ute the understanding of human disease? Furthermore,
clinical scientists may be too distracted by the intensity of
clinical care to be able to seriously help bridge this gap.
Are clinical research grants providing sufficient support to
academic clinicians to truly promote translational
research [19]? For instance, traditionally, R01 grants have
been used to measure a scientist's "independence". How-
ever, such approach may distance newer basic or clinical
investigators from the integrated approach often required
for translational efforts. Should advocacy efforts voice the
importance of more interdisciplinary grants?
Confounding the whole picture is the fact that transla-
tional research is not pristine [11]. This is partly due to the
constraints and inconsistencies of dealing with human
subjects. It is at once true that review standards for grant
applications and publications need to account for this
unavoidable "sloppiness", and that clinical studies must
be better designed prospectively to address biological
questions beyond the routine assessment of safety and
clinical efficacy. This could be achieved by prospectively
collecting biological material of broad scientific interest at
time points relevant to the natural or treatment-induced
history of a disease and applying modalities appropriate
for the exploitation of modern scientific tools. Clinical
scientists, particularly those not extensively and currently
exposed to bench research, should receive special training
to become at least informed of the ever growing scientific
opportunities for translational research [19-23]. This lim-
itation leads to simple lack of manpower. At present there
are few training programs that are ideally geared toward
teaching all aspects of translational research. Although
there are some attempts at developing clinical research
training programs as evidenced by the NIH initiative and
the Doris Duke Charitable Foundation funding for medi-
cal students to spend one year engaged in clinical research
programs, itis not clear that this will significantly impact
the manpower shortage. Translational investigators must
not only be familiar with the regulatory, statistical and
administrative issues related to clinical investigation, but
must also possess a highly specialized expertise in the
basic science underlying the new technology or pharma-
cologic agents. At a time when there are more agents to
test than ever before, it is problematic that medical
schools and medical education programs are not ready to
train physicians in translational research. Programs pro-
viding interested applicants with experience in both basic
science and clinical investigation may be necessary to
maintain a pool of competent translational researchers.
Furthermore, role models need to be developed for stu-
dents and young investigators to begin to encourage the
brightest students to enter this highly rewarding field.
Regulatory
Regulatory requirements provide formidable challenges
for investigators. Major efforts have been made by regula-
tory agencies by releasing guidance documents. However,
several obstacles remain. For example, preclinical evi-
dence is usually required despite its unclear relevance to
human disease. Similarly, it remains unclear whether tox-
icity testing in animal models is relevant to humans, par-
ticularly when biological agents with strong species-
specificity are considered. Perhaps directly testing in
humans, particularly for life threatening diseases when
standard therapies have failed, should be considered in a
limited number of patients. Clinical trial designs for the
early development of novel therapies could be simplified
according to the anticipated biologic activity of the agent
tested [24]. While biopharmaceutical companies employ
contractors or staff to address and meet regulatory require-
ments as required by regulations and the law, many aca-
demic institutions do not provide appropriate regulatory
support. Most translational research is supported by
grants; however, few provide funding for regulatory staff
or consultation. Academic institutions do not provide
support to non hypothesis driven research such as product
development. In addition, a grant application focused on
translational research characterizing identity, purity, sta-
bility and potency is rarely funded. Yet these characteris-
tics are needed for advance testing of novel agents.
By the time new therapies work their way through preclin-
ical experimentation, clinical studies and Phase III stud-
ies, they are often no longer state-of-the art and may even
be scientifically obsolete. Therapeutic efficacy in the form
of survival advantage remains a pre-requisite for regula-
tory approval of new therapies for cancer. This require-
ment is a major financial burden for small industries since
the long term costs of clinical testing have to be sustained
without economic return. This problem is compounded
for tailored therapies such those directed against specific
cancer mutations that target smaller market sizes while
their development costs remain the same.
Paradoxically, many currently accepted therapies are
known to provide no statistically significant survival ben-
efit yet they have both approval for distribution and cov-
erage by insurance companies. The National Cancer
Institute leadership has recently put emphasis on "discov-
ery, development and delivery" (NCI Director's report
2003) and, with the purpose of eliminating or reducing
obstacles in translational research, the NCI Director's
office has appointed new deputies charged with stream-
lining the discovery to delivery process. This strategy will
hopefully yield results, at least in the context of cancer
research, in a new modus operandi in clinical research
where new agents could be quickly moved through the
process and either approved or discarded.Journal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/14
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Obviously, regulatory problems are not only limited to
the development and distribution of new therapeutics.
Institutional Review Boards and other internal review
processes implement "ad hoc" rules to protect patients'
safety and privacy based on the well established principle
of "primum non nuocere, i.e. do no harm". Yet, it remains
questionable as to whether this theoretical need to protect
sufficiently balances the overwhelming desire of patients'
to attempt novel therapies when all other options are
exhausted.
Economic
The current uni-directional paradigm of bench to bedside
translational research is not cost-effective when one con-
siders the long term expenditure of testing new drugs pre-
clinically, obtaining regulatory approval for testing in
humans and organizing increasingly larger clinical studies
to demonstrate long-term clinical efficacy. How can small
or medium biotechnology firms justify these costs? Simi-
larly, how can academic institutions seeking to translate
ideas of their research faculty take the economical risk of
supporting a promising clinical trial? Should the cost of
clinical trials be partly covered by insurance? How can Big
Pharma justify the price of translational medicine? Aca-
demic clinical centers currently have an incentive to re-try
combination trials based on permutations of approved
treatments. These trials, at best, result in incremental ther-
apeutic and scientific returns. Real and effective academic
translational research centers are slowly growing but they
have to confront tremendous economic challenges since
their funding continues to depend predominantly on
industry, grants from federal and non federal agencies and
philanthropy.
It may be possible to create a solvent system for transla-
tional research if the well-designed but standard biologi-
cal studies are combined with already approved therapies.
For instance, interleukin-2 has been approved for the
treatment of renal cell cancer and melanoma, yet the
mechanism responsible for cancer rejection remains
unknown. Centers could implement studies that generate
revenue and provide material for biological studies while
at the same time contribute to the support of novel exper-
imental therapies.
Conclusion
There are three major obstacles to effective translational
medicine. The first is the challenge of translating basic sci-
ence discoveries into clinical studies. The second hurdle is
the translation of clinical studies into medical practice
and health care policy [7]. A third obstacle to effective
translational medicine is also philosophical. It is a fact
that the available standard therapies for most common
diseases are less efficacious than they are believed by the
Public to be and significant funds are allocated to main-
tain this "placebo" effect through standard care. Propor-
tionately, very little is spent to identify truly effective
therapies. Finally, it may be a mistake to think that basic
science, without observations from the clinic and without
epidemiological findings of possible associations between
different noxes and disease, will efficiently produce the
novel therapies that we are eager to test. If we as a body
can coordinate efforts by advocacy groups, academia and
industry to educate the public and the government of the
need for translational medicine, novel and effective thera-
pies could be the significant result.
In the upcoming Translational Research conference to be
held September 20–22, 2004 in Princeton (for more
information visit: http://www.iqpc.com/NA-2166-01/
translationalresearch) we will be addressing these critical
issues.
Comments are welcome and should be directed to: http:/
/FMarincola@cc.nih.gov or directly submitted to JTM at
http://www.translational-medicine.com).
This editorial was prepared in Dr Marincola's private
capacity. No official support or endorsement by the
National Institutes of Health is intended or should be
inferred.
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